A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease (AD), Including a Placebo-Treated Noncarrier Cohort
|2||Active, not recruiting||
Central and Systemic Inflammation in Alzheimer's Disease
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
|4||Active, not recruiting||
Genetics of Mendelian Forms of Young Onset Alzheimer Disease
† Study has passed its completion date and status has not been verified in more than two years.